Serum Autoantibodies against STIP1 as a Potential Biomarker in the Diagnosis of Esophageal Squamous Cell Carcinoma

Table 2

Frequency of autoantibodies against STIP1.

Group	N	Positive (%, 95% CI)	value
Training cohort
All ESCC	148	62 (41.9%, 33.9%–50.3%)	<0.0001
Early-stage ESCC (0 + I + IIA)	42	15 (35.7%, 22.0%–52.0%)	<0.0001
Normal controls	111	11 (9.9%, 5.3%–17.4%)
Validation cohort
All ESCC	60	24 (40.0%, 27.8%–53.5%)	<0.0001
Early-stage ESCC (0 + I + IIA)	13	5 (38.5%, 15.1%–67.7%)	<0.05
Normal controls	40	3 (7.5%, 2.0%–21.5%)

ESCC: esophageal squamous cell carcinoma; value is relative to normal controls. Statistical significance was determined using unpaired chi-square test.